[1]孙红爽,乜春城,朱小丽,等.11β-HSD1在糖皮质激素联合高脂喂养 大鼠胰岛素抵抗中的作用[J].国际内分泌代谢杂志,2016,36(01):14-19.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
　Sun Hongshuang*,Nie Chuncheng,Zhu Xiaoli,et al.Effects of 11β-hydroxysteroid dehydrogenase type 1 on insulin resistance in rats induced by glucocorticoid and high fat diet[J].International Journal of Endocrinology and Metabolism,2016,36(01):14-19.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
点击复制

11β-HSD1在糖皮质激素联合高脂喂养 大鼠胰岛素抵抗中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
36
期数:
2016年01期
页码:
14-19
栏目:
论著
出版日期:
2016-01-20

文章信息/Info

Title:
Effects of 11β-hydroxysteroid dehydrogenase type 1 on insulin resistance in rats induced by glucocorticoid and high fat diet
作者:
孙红爽; 乜春城; 朱小丽; 马红芳; 陈赫军; 种宝贵
053000 衡水,哈励逊国际和平医院药学部(孙红爽,朱小丽,马红芳,陈赫军,种宝贵),生殖医学科 (乜春城)
Author(s):
Sun Hongshuang*;  Nie Chuncheng;  Zhu Xiaoli;  Ma Hongfang;  Chen Hejun;  Chong Baogui.
*Department of Pharmaceutical, Harrison International Peace Hospital, Hengshui 053000,China
关键词:
11β-羟类固醇脱氢酶1;  糖皮质激素;  地塞米松;  高脂饮食;  大鼠
Keywords:
11β-hydroxysteroid dehydrogenase type 1;  Glucocorticoid;  Dexamethasone;  High-fat diet;  Rats
DOI:
10.3760/cma.j.issn.1673-4157.2016.01.004
摘要:
目的 通过糖皮质激素联合高脂喂养建立胰岛素抵抗动物模型,探讨11β-羟类固醇脱氢酶1(11β-HSD1)在该模型中的表达和意义。方法 32只雄性Wistar大鼠,按体重随机区组法分为对照组、地塞米松组、高脂饮食组、高脂+地塞米松组(HFD+DEX组),每组8只。对照组和地塞米松组喂以普通饲料,高脂饮食组和HFD+DEX组喂以高脂饲料,8周后地塞米松组和HFD+DEX组辅以地塞米松刺激,12周后进行胰岛素耐量试验,检测血糖、血脂、血胰岛素及皮质酮水平,计算肝指数、内脏肥胖指数及稳态模型评估-胰岛素抵抗(HOMA-IR)指数,检测11β-HSD1基因及蛋白表达情况。结果 与对照组相比,其余3组均出现胰岛素抵抗,表现为:胰岛素耐量试验不敏感(注射胰岛素30 min后对照组、高脂饮食组、地塞米松组和HFD+DEX组血糖值分别下降了44.15%,28.14%,32.58%,13.53%)、高血糖、高胰岛素血症、血脂紊乱(总胆固醇、甘油三酯及游离脂肪酸升高,高密度脂蛋白-胆固醇降低)、HOMA-IR指数、肝指数及内脏肥胖指数升高,且HFD+DEX组各项指标变化幅度最大(F=10.89～213.20,P<0.05或P<0.01)。另外,与对照组相比,其余3组内脏脂肪组织11β-HSD1基因及蛋白表达水平也明显升高,且HFD+DEX组明显高于高脂饮食组及地塞米松组(F=32.64～116.00, P均<0.01)。结论 地塞米松联合高脂饮食喂养可成功建立大鼠胰岛素抵抗模型,内脏脂肪组织中11β-HSD1基因及蛋白表达升高,可能与胰岛素抵抗的发生密切相关。
Abstract:
Objective To set up an insulin-resistant(IR)animal model by glucocorticoid and high-fat diet, and investigate the expressionof 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1)in this model and its significance. Methods Thirty-two male Wistar rats were randomly divided into four groups according to body weight randomized blocks: control group, dexamethasone group(DEX group),high-fat diet group(HFD group),and high-fat diet plus dexamethasone group(HFD+DEX group), with 8 rats in each group. Rats in control group and DEX group were fed with standard rat chow diet, while rats in HFD group and HFD+DEX group were fed with fat- and sugar-enriched diet. After 8 weeks,dexamethasone was injected subcutaneously to DEX group and HFD+DEX group. After 12 weeks, insulin tolerance test was performed, and levels of blood glucose, lipid, insulin and corticosterone were measured. Liver index, visceral obesity index and homeostasis model assessment for insulin resistance(HOMA-IR)were calculated,the expression of 11β-HSD1 gene and protein were measured. Results Compared with control group, IR was successfully induced in the other three groups, characterized by insensitivity in insulin tolerance test(30 minutes after insulin injection, blood glucose decreased by 44.15%,28.14%,32.58% or 13.53% in control group,HFD group,DEX group and HFD+DEX group, respectively), hyperglycosemia, hyperinsulinemia, dyslipidemia(elevated total cholesterol, triglyceride and free fatty acids, but reduced high density lipoprotein cholesterol), and the increase of HOMA-IR, hepatic index and visceral obesity index, especially in HFD+DEX group(F=10.89-213.20,P<0.05 or <0.01). In addition, compared with control group, levels of 11β-HSD1 mRNA and protein in visceral adipose tissue of the other three groups were increased significantly, especially in HFD+DEX group(F=32.64-116.00, P<0.01). Conclusion The combination of dexamethasone and high-fat diet can induce IR in rat successfully, and the expression of 11β-HSD1 mRNA and protein in viseral adipose tissue are increased,which may be closely related to the occurrence of IR.

参考文献/References:

[1] 谭莉莉,孙红爽,谢生荣,等.高脂高糖饲料喂养结合慢性应激促进大鼠胰岛素抵抗[J]. 中国药科大学学报,2009,40(4):380-384.DOI: 10.3321/j.issn:1000-5048.2009.04.018.
[2] Gao S,Han X,Fu J,et al. Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet[J].Hepatol Res,2012,42(7):686-695.DOI:10.1111/j.1872-034X.2011.00961.x.
[3] 孙红爽,郑文卿,刘雯,等. 急性或慢性应激对高热量饲料喂养大鼠HPA轴的影响 [J]. 安徽医药, 2010, 14(1): 17-19.DOI: 10.3969/j.issn.1009-6469.2010.01.007.
[4] 张小华,张汝学,贾正平,等. 高脂饮食和地塞米松联合诱导胰岛素抵抗大鼠模型 [J].中国实验动物学报,2008,16(5):325-329.DOI: 10.3969/j.issn.1005-4847.2008.05.002.
[5] 孙晓晖, 陈文双, 陈春玲, 等. 长期使用糖皮质激素对大鼠的骨生物力学影响[J]. 中国骨质疏松杂志, 2015, 21(4): 418-451.
[6] Auvinen HE,Coomans CP,Boon MR,et al. Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet[J].Physiol Rep,2013,1(5):e00103.DOI:10.1002/phy2.103.
[7] 张萍,李圣贤,刘伟. 11β-羟类固醇脱氢酶1与胰岛素抵抗和多囊卵巢综合征 [J].国际内分泌代谢杂志, 2012, 32(2):103-106.DOI: 10.3760/cma.j.issn.1673-4157.2012.02.010.
[8] Schnackenberg CG,Costell MH,Krosky DJ,et al. Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulinresistance, and hypertriglyceridemia in metabolic syndrome[J].Biomed Res Int,2013,2013:427640. DOI:10.1155/2013/427640.
[9] Yoon DS,Wu SC,Seethala R,et al. Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1(11β-HSD1)inhibitors for thetreatment of metabolic disorders[J].Bioorg Med Chem Lett,2014,24(21):5045-5049. DOI:10.1016/j.bmcl.2014.09.012.
[10] Okazaki S,Takahashi T,Iwamura T,et al. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, amelioratesinsulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models[J].J Pharmacol Exp Ther,2014,351(1):181-189. DOI:10.1124/jpet.114.216556.
[11] Holmes MC,Seckl JR. The role of 11beta-hydroxysteroid dehydrogenases in the brain[J].Mol Cell Endocrinol,2006,248(1-2):9-14.
[12] Hult M,Shafqat N,Elleby B,et al. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons[J].Mol Cell Endocrinol,2006,248(1-2):26-33.
[13] Feig PU,Shah S,Hermanowski-Vosatka A,et al. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome[J].Diabetes Obes Metab,2011,13(6):498-504.DOI: 10.1111/j.1463-1326.2011.01375.x.
[14] Rosenstock J,Banarer S,Fonseca VA,et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy[J].Diabetes Care,2010,33(7):1516-1522. DOI:10.2337/dc09-2315.
[15] Arakaki R,Welles B. Ketoconazole enantiomer for the treatment of diabetes mellitus[J].Expert Opin Investig Drugs,2010,19(2):185-194. DOI:10.1517/13543780903381411.
[16] Feng Y,Huang SL,Dou W,et al. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and amelioratesmetabolic disorder in diet-induced obese mice[J].Br J Pharmacol,2010,161(1):113-126.DOI:10.1111/j.1476-5381.2010.00826.x.
[17] Blum A,Loerz C,Martin HJ,et al. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11β-hydroxysteroiddehydrogenase type 1 inhibitor[J].J Steroid Biochem Mol Biol,2012,128(1-2):51-55.DOI:10.1016/j.jsbmb.2011.09.003.

相似文献/References:

[1]曹琳 郑仁东 曹雯 许娟 孙洪平 刘超.甲状腺相关性眼病治疗新进展[J].国际内分泌代谢杂志,2019,39(01):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
　Cao Lin,Zheng Rendong,Cao Wen,et al.Update on the management of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2019,39(01):25.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
[2]余静雯 胡欣 叶向荣 陈彦 刘超.2021年欧洲甲状腺学会/欧洲Graves眼病专家组Graves眼病管理指南:解读与思考[J].国际内分泌代谢杂志,2022,42(04):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
　Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(01):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
[3]陆晨雅,陈国芳,徐书杭,等.甲状腺相关性眼病处理的新视角:局部注射疗法[J].国际内分泌代谢杂志,2023,43(02):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
　Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(01):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
[4]郭伟红,何庆.21-羟化酶缺陷症的围妊娠期管理研究进展[J].国际内分泌代谢杂志,2023,43(02):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
　Guo Weihong,He Qing..Peripregnancy management of 21-hydroxylase deficiency[J].International Journal of Endocrinology and Metabolism,2023,43(01):128.[doi:10.3760/cma.j.cn121383-20211202-12006]

备注/Memo

备注/Memo:
基金项目:河北省2015年度医学科学研究课题(20150432)
更新日期/Last Update: 2016-01-20